The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
| Date | Insider | Role | Action | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Feb 9, 2026 | Jaiman Manasi | Chief Medical Officer | Grant(A) | 71K | — | $0 |
| Feb 9, 2026 | Lee Tien-Li | Chief Executive Officer, Director, 10% Owner | Grant(A) | 204K | — | $0 |
| Feb 9, 2026 | Sun Nelson | Chief Financial Officer | Grant(A) | 71K | — | $0 |
| Dec 11, 2025 | Lee Tien-Li | Chief Executive Officer, Director, 10% Owner | Buy(P) | 7K | $14.49 | $101K |
| Dec 11, 2025 | Sun Nelson | Chief Financial Officer | Buy(P) | 3K | $14.40 | $43K |
| Oct 15, 2025 | Jones Bryan | Chief Operating Officer | Option exercise(M) | 1K | $4.24 | $5K |
| Oct 15, 2025 | Jones Bryan | Chief Operating Officer | Option exercise(M) | 1K | — | $0 |
| Oct 15, 2025 | Lee Tien-Li | Chief Executive Officer, Director, 10% Owner | Option exercise(M) | 1K | $4.24 | $5K |
| Oct 15, 2025 | Lee Tien-Li | Chief Executive Officer, Director, 10% Owner | Option exercise(M) | 1K | — | $0 |
| Sep 15, 2025 | Lee Tien-Li | Chief Executive Officer, Director, 10% Owner | Buy(P) | 7K | $9.51 | $62K |
| Sep 15, 2025 | Lee Tien-Li | Chief Executive Officer, Director, 10% Owner | Buy(P) | 4K | $9.94 | $35K |
| Sep 12, 2025 | Lee Tien-Li | Chief Executive Officer, Director, 10% Owner | Buy(P) | 5K | $8.50 | $43K |
| Sep 11, 2025 | Lee Tien-Li | Chief Executive Officer, Director, 10% Owner | Buy(P) | 6K | $7.82 | $47K |
| Sep 10, 2025 | Lee Tien-Li | Chief Executive Officer, Director, 10% Owner | Buy(P) | 9K | $7.91 | $71K |
| Sep 9, 2025 | Sun Nelson | Chief Financial Officer | Buy(P) | 6K | $8.07 | $48K |
| Aug 28, 2025 | Lee Tien-Li | Chief Executive Officer, Director, 10% Owner | Option exercise(M) | 17K | $4.24 | $73K |
| Aug 28, 2025 | Lee Tien-Li | Chief Executive Officer, Director, 10% Owner | Option exercise(M) | 17K | — | $0 |
| Jun 11, 2025 | Graf Susan E | Director | Grant(A) | 31K | — | $0 |
| Jun 11, 2025 | Jones Bryan | Chief Operating Officer | Grant(A) | 122K | — | $0 |
| Jun 11, 2025 | Tong Victor Edward Jr | Director | Grant(A) | 61K | — | $0 |
| Jun 11, 2025 | Baynes Roy D. | Director | Grant(A) | 31K | — | $0 |
| Jun 11, 2025 | Sun Nelson | Chief Financial Officer | Grant(A) | 210K | — | $0 |
| Jun 11, 2025 | Jaiman Manasi | Chief Medical Officer | Grant(A) | 127K | — | $0 |
| Jun 11, 2025 | Chi Jeffrey | Director | Grant(A) | 61K | — | $0 |
| Jun 11, 2025 | Lee Tien-Li | Chief Executive Officer, Director, 10% Owner | Grant(A) | 550K | — | $0 |
| Feb 14, 2025 | Chen Bihua | Insider | Buy(P) | 188K | $16.00 | $3.0M |
| Feb 14, 2025 | Chen Bihua | Insider | Conversion(C) | 800K | — | — |
| Feb 14, 2025 | Chen Bihua | Insider | Conversion(C) | 6.8M | — | — |
| Feb 14, 2025 | Sun Nelson | Chief Financial Officer | Buy(P) | 10K | $16.00 | $160K |
| Feb 14, 2025 | Sun Nelson | Chief Financial Officer | Conversion(C) | 7K | — | — |
| Feb 14, 2025 | Sun Nelson | Chief Financial Officer | Conversion(C) | 59K | — | $0 |
| Feb 14, 2025 | Lee Tien-Li | Chief Executive Officer, Director, 10% Owner | Buy(P) | 17K | $16.00 | $265K |
| Feb 14, 2025 | Lee Tien-Li | Chief Executive Officer, Director, 10% Owner | Conversion(C) | 41K | — | — |
| Feb 14, 2025 | Lee Tien-Li | Chief Executive Officer, Director, 10% Owner | Conversion(C) | 350K | — | $0 |
| Feb 14, 2025 | Vickers Venture Fund VI Pte Ltd | 10% Owner | Conversion(C) | 1.6M | — | — |
| Feb 14, 2025 | Vickers Venture Fund VI Pte Ltd | 10% Owner | Conversion(C) | 413K | — | — |
| Feb 14, 2025 | Vickers Venture Fund VI Pte Ltd | 10% Owner | Conversion(C) | 13.9M | — | $0 |
| Feb 14, 2025 | Vickers Venture Fund VI Pte Ltd | 10% Owner | Conversion(C) | 3.5M | — | $0 |
| Feb 14, 2025 | Chi Jeffrey | Director | Conversion(C) | 133K | — | — |
| Feb 14, 2025 | Chi Jeffrey | Director | Conversion(C) | 1.1M | — | $0 |
| Feb 14, 2025 | Decheng Capital Global Life Sciences Fund IV, L.P. | 10% Owner | Conversion(C) | 2.3M | — | — |
| Feb 14, 2025 | Decheng Capital Global Life Sciences Fund IV, L.P. | 10% Owner | Buy(P) | 625K | $16.00 | $10.0M |
| Feb 14, 2025 | Decheng Capital Global Life Sciences Fund IV, L.P. | 10% Owner | Buy(P) | 625K | $16.00 | $10.0M |
| Feb 14, 2025 | Decheng Capital Global Life Sciences Fund IV, L.P. | 10% Owner | Conversion(C) | 333K | — | — |
| Feb 14, 2025 | Decheng Capital Global Life Sciences Fund IV, L.P. | 10% Owner | Conversion(C) | 19.8M | — | $0 |
| Feb 14, 2025 | Decheng Capital Global Life Sciences Fund IV, L.P. | 10% Owner | Conversion(C) | 2.8M | — | $0 |
Insider transactions sourced from SEC EDGAR Form 4 filings, normalized within minutes of acceptance. "Buy"/"Sell" mark open-market transactions (codes P/S), the tradeable signal. Awards, option exercises and tax-withholding are shown with their raw code. All data is public domain.
Coverage: Form 4 filings indexed 2021-03-29 → 2026-07-14. Earlier history is backfilling; this window widens as it deepens.
Programmatic access via the Arkolith API & MCP server (insider.transactions, insider.company).